S-1/A: CTT Pharma Files for Resale of Shares via Equity Line

CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement to allow for the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners, issued under a committed equity line of credit.

Summary

• CTT Pharmaceutical Holdings, Inc. (CTT Pharma) is filing an amended registration statement (Form S-1) to permit RH2 Equity Partners (the Selling Stockholder) to resell up to 6,250,000 shares of common stock.
• These shares were issued or may be issued to the Selling Stockholder under an Equity Line of Credit Agreement (ELOC) dated September 19, 2025.
• CTT Pharma will not receive proceeds from the resale of these shares by the Selling Stockholder, but may receive up to $10 million in gross proceeds from future sales to the Selling Stockholder under the ELOC.
• The company intends to use any proceeds from the ELOC for working capital, strategic initiatives, and general corporate purposes, with a priority to invest in manufacturing equipment.
• The company is a development-stage company focused on fast-dissolving drug delivery systems, specifically oral dissolvable strips, with current efforts focused on nicotine and vitamin strips.
• The company has a history of losses and its auditors have included a going concern qualification.
• The company's common stock is listed on the OTCQB under the symbol CTTH, with a recent closing price of $0.08 per share as of June 26, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's development-stage status, history of losses, going concern warning, and the dilutive nature of its primary financing mechanism (ELOC), despite the potential of its technology.

Positives

• Secured a $10 million Equity Line of Credit (ELOC) with RH2 Equity Partners to fund future operations and development.
• Development of patented fast-dissolving oral strip technology with potential applications in pharmaceuticals, nutraceuticals, and nicotine products.
• Focus on nicotine and vitamin strips as initial commercialization targets, with vitamin strips not requiring FDA approval for market entry.
• Received a Continuation in Part (CIP) application approval from the US Patent Office for nicotine strips, strengthening patent protection.
• In preliminary discussions with a European company for a potential partnership.
• Management is focused on bringing manufacturing in-house, with plans to acquire equipment.
• The company has a history of securing patents and is actively working to protect its intellectual property.

Negatives

• The company is in a development stage and has a history of significant losses, with auditors raising substantial doubt about its ability to continue as a going concern.
• The company has limited operating history and has not generated significant revenue to date.
• The ELOC financing may result in substantial dilution to existing shareholders, especially at current low stock prices.
• The company faces significant regulatory hurdles, particularly for nicotine products requiring FDA approval, which can be lengthy and costly.
• The company has material weaknesses in its internal controls, including a lack of written documentation and insufficient segregation of duties.
• The market for the company's common stock is limited and volatile, and it is subject to penny stock regulations.
• The company does not anticipate paying dividends in the foreseeable future.

Risks

• The company may never achieve operational success as it is in a development stage.
• The ELOC financing could lead to significant dilution of existing shareholders' ownership.
• The company has a history of losses and its auditors have issued a going concern qualification.
• The company has generated limited operating revenue and expects further losses.
• The company is subject to extensive and costly governmental regulation, particularly for nicotine products.
• The company may incur substantial product liability expenses.
• Delays in commercializing the strip technology could adversely affect the business.
• The company may not be able to adequately protect its patent and proprietary rights.
• The company faces rapid technological change and intense competition from larger, well-resourced companies.
• The company may not be able to adequately manage its growth.
• The loss of executive officers or key employees could have a material adverse effect.
• The company has only one independent director and is working to appoint a second to meet OTCQB standards.
• Management controls a significant percentage of the outstanding common stock, potentially influencing corporate decisions.
• Intellectual property infringement claims could be expensive and may not be successful.
• The company may incur significant increased costs as a result of operating as a public company.
• The company's common stock is subject to penny stock regulations, which may affect its liquidity and ability to raise capital.
• The company has never declared a cash dividend and does not intend to in the foreseeable future.
• Product recalls could adversely affect the company's brand image and financial performance.
• The company's systems and data may be subject to security incidents or alleged violations of data handling laws.
• The company is an emerging growth company and a smaller reporting company, availing itself of reduced disclosure requirements which could make its stock less attractive.
• The actual number of shares sold under the ELOC and the proceeds received are uncertain.
• Future sales of common stock could cause the price to decline and make it difficult to secure additional financing.
• The company may require additional financing to sustain operations and may not be able to continue operations without it.
• The company's management will have broad discretion over the use of proceeds, which may not improve its financial condition or market value.

Future Outlook

The company plans to use proceeds from the ELOC for working capital, strategic initiatives, and general corporate purposes, with a priority on acquiring manufacturing equipment. They aim to launch nicotine and vitamin strips in 2026. Future pharmaceutical product development is expected to be pursued through partnerships. The company anticipates continued operating losses in the near term.

Management Comments

• The CEO has been mindful of not diluting shareholders and will continue to make decisions that are in the best interests of shareholders.
• Management believes that if our stock price substantially increases that we will be required to sell substantially fewer shares under the ELOC to reach our goals and that this will reduce dilution to our shareholder, but no assurance can be given that this will occur.
• We would look to raise additional funding if the stock goes over $1.00 a share.
• The CEO of CTT has identified a real need for our technology in the tobacco/nicotine industry as more than 480,000 Americans die each year from the effects of smoking or 1300 per day and more than 8 million deaths worldwide.
• Management believes that the proceeds of this offering will allow the Company to acquire its own machinery to produce its strips and result in substantial benefit to our shareholders.
• Management believes that our orally dissolving strips could be an excellent fast dissolving drug delivery system which can be used by veterinarians to treat dogs, cats and other animals who would ordinarily be given a pill or injection.

Industry Context

StockSavvy.ai notes that CTT Pharma operates in the highly competitive drug delivery and pharmaceutical sector. The company's focus on oral dissolvable strips for nicotine and vitamin products positions it within growing markets, but faces significant regulatory challenges for nicotine products and intense competition from established players in both the pharmaceutical and consumer health sectors. The company's strategy to bring manufacturing in-house and pursue partnerships for pharmaceutical applications aligns with industry trends for emerging companies seeking to control costs and leverage expertise.

Comparison to Industry Standards

• The company's focus on oral dissolvable strips is a niche within the broader drug delivery market, which includes transdermal patches, injections, and traditional oral tablets. Companies like LTS Lohmann Therapie-Systeme AG and Patheon (part of Thermo Fisher Scientific) offer advanced drug delivery solutions, though often for more established pharmaceutical products.
• In the nicotine replacement therapy (NRT) market, CTT Pharma competes with established products like Nicorette (gum) and Nicoderm (patch) from Johnson & Johnson, as well as newer entrants in the e-cigarette and nicotine pouch markets. The regulatory pathway for nicotine products in the US (Premarket Tobacco Product Application - PMTA) is rigorous, similar to the drug approval process for NRTs, requiring extensive safety and efficacy data.
• The company's financial performance, characterized by significant net losses and a going concern warning, is common among early-stage biotechnology and pharmaceutical companies investing heavily in R&D and regulatory processes. However, its current market capitalization and revenue generation are significantly lower than established players in the pharmaceutical industry.
• The company's reliance on an equity line of credit (ELOC) is a common, albeit dilutive, financing method for development-stage companies lacking traditional revenue streams or access to debt financing. This contrasts with larger pharmaceutical companies that typically fund operations through product sales, licensing agreements, or more traditional equity offerings.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the ELOC financing, but also potential for future value if the company's technology is successfully commercialized. Current stock price volatility is a concern.
• Employees: The company plans to hire additional employees as funds become available, which could lead to job creation.
• Suppliers: The company sources raw materials from third-party suppliers. Bringing manufacturing in-house may alter supplier relationships.
• Creditors: The company's going concern status and history of losses may impact its ability to service debt, though no significant debt is currently disclosed.

Next Steps

• The company aims to launch nicotine and vitamin dissolvable strips in 2026.
• The company intends to acquire manufacturing equipment to bring production in-house.
• The company will continue to seek regulatory approval for nicotine products in the US.
• The company may pursue strategic partnerships for pharmaceutical product development.
• The company is seeking to appoint a second independent director to comply with OTCQB standards.

Key Dates

Recommendation

The company possesses innovative technology with potential in multiple markets, particularly nicotine and vitamin strips. However, significant risks remain, including its development-stage status, history of losses, auditor's going concern opinion, and the dilutive nature of its financing. While the ELOC provides a path forward, it introduces substantial dilution. The regulatory pathway for nicotine products is also a key uncertainty. Given these factors, a 'hold' recommendation is appropriate, suggesting investors monitor progress on regulatory approvals, commercialization efforts, and financing strategies before considering a more aggressive stance.

Keywords

CTT Pharmaceutical Holdings, S-1 Amendment, Equity Line of Credit, RH2 Equity Partners, Common Stock Resale, Drug Delivery Systems, Oral Dissolvable Strips, Nicotine Strips, Vitamin Strips, Development Stage Company, Going Concern, Dilution, SEC Filing, OTCQB, CTTH